Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

December 11, 2025

Dyne Therapeutics (DYN) Navigates a Paradoxical Day: Positive Clinical Data Overshadowed by Dilution Fears

December 09, 2025

New York, NY – December 9, 2025 – Dyne Therapeutics (NASDAQ: DYN) found itself in an unusual spotlight today, emerging as a significant market mover, albeit in a direction that belied ostensibly...

Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results

December 03, 2025

December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an...

Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam.

How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint ↗

December 02, 2025

Via Investor's Business Daily

Sarepta Wins FDA Approval To Begin Study On Reducing Liver Injury Risk With Elevidys ↗

November 25, 2025

The data from the study cohort will be used to determine whether administering sirolimus before and after the ELEVIDYS infusion can help reduce acute liver injury, the company said.

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

November 25, 2025

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

November 24, 2025

Tech Edges Up Ahead Of Nvidia's Earnings, Bitcoin Sinks Below $90,000: What's Moving Markets Wednesday? ↗

November 19, 2025

All eyes are on Nvidia Corp. (NASDAQ:NVDA) as the world's most valuable company prepares to report third-quarter earnings after the close, a pivotal moment that could steer

Via Benzinga

Sarepta Stock Slides Premarket After New FDA Warning Shrinks Market For Its $3.2M DMD Gene Therapy ↗

November 17, 2025

FDA added a boxed warning to Elevidys after two pediatric deaths and imposed stricter monitoring rules.

There might be plenty more downside for these biotechs.

Topics Death

2 Beaten-Down Stocks to Avoid Right Now ↗

November 15, 2025

Via The Motley Fool

Topics Death

Sarepta Shares Jump After FDA Approves Updated Elevidys Label ↗

November 14, 2025

Sarepta Therapeutics shares jumped after the FDA issued a new boxed warning for Elevidys.

Via Benzinga

Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information

November 14, 2025

The financial markets are a complex ecosystem, constantly reacting to a myriad of inputs, from macroeconomic data to geopolitical shifts. Among the most closely watched catalysts are the pronouncements...

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 11, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

November 05, 2025

Via Benzinga

Analyst Ratings Send Ripples Through Markets: Sarepta's Resilience vs. Pinterest's Plunge

November 05, 2025

This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗

November 05, 2025

Via Benzinga

Sarepta Therapeutics Shares Plummet as Key DMD Treatments Miss Primary Endpoint in Late-Stage Trial

November 04, 2025

Sarepta Therapeutics Inc. (NASDAQ: SRPT) experienced a dramatic downturn in its stock valuation today, November 4, 2025, following the announcement of disappointing results from a pivotal late-stage...

Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.

Topics Death

Which stocks are experiencing notable movement on Tuesday? ↗

November 04, 2025

Via Chartmill

Gold Falls Over 1%; Uber Shares Decline After Q3 Results ↗

November 04, 2025

Via Benzinga

Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance ↗

November 04, 2025

Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid Elevidys sales weakness.

Via Benzinga

Tuesday's session: top gainers and losers ↗

November 04, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It ↗

November 04, 2025

Enough though Sarepta shares are crashing, "Pharma Bro" Martin Shkreli says he still likes the stock.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 04, 2025

Via Benzinga

These stocks are gapping in today's session ↗

November 04, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

Insperity Posts Downbeat Q3 Results, Joins IAC, Archer-Daniels-Midland And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

November 04, 2025

Via Benzinga

Tuesday's pre-market session: top gainers and losers ↗

November 04, 2025

The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 04, 2025

Via Benzinga

Dow Futures Edge Lower On Pullback Fears: PLTR, SRPT, TSLA, AMD Among Stocks To Watch ↗

November 04, 2025

While Dow Jones futures were down by 0.72% at the time of writing, the S&P 500 futures fell 1.02%.